Vaccines, Vol. 12, Pages 355: Intranodal Injection of Immune Activator Demonstrates Antitumor Efficacy in an Adjuvant Approach

Vaccines, Vol. 12, Pages 355: Intranodal Injection of Immune Activator Demonstrates Antitumor Efficacy in an Adjuvant Approach

Vaccines doi: 10.3390/vaccines12040355

Authors: Romano Josi Anete Ogrina Dominik Rothen Ina Balke Arnau Solé Casaramona Simone de Brot Mona O. Mohsen

The tumor-draining lymph nodes (tdLN) are the initial site of metastases and are the prime site for generating robust antitumor responses. In this study, we explored the efficacy of a universal immune activator (ImmAct) targeted to the tdLN. This approach can be viewed as an attempt to turn a cold, unresponsive tdLN into a hot, responsive site. The adjuvant antitumor efficacy of our novel intranodal injection was evaluated in an aggressive metastatic mammary carcinoma murine model. The cancer cells were inoculated subcutaneously in the lower quadrant of the mouse to provoke the tdLN (inguinal lymph node). The study encompasses a range of methodologies, including in vivo and in vitro assays and high-dimensional flow cytometry analysis. Our findings demonstrated that intranodal administration of ImmAct following the dissection of the primary tumor led to improved tumor-free survival and minimized weight loss. ImmAct led to both local and systemic alterations in the cellular and humoral immunity. Additionally, after ImmAct treatment, non-responders showed a higher rate of exhausted CD8+ T cells compared to responders. Indeed, our innovative approach surpassed the gold standard surgery of sentinel lymph node excision. Overall, intranodal administration of ImmAct yielded a robust antitumor immune response, offering protection against micrometastases and relapse.